山西治自创医院山西痔疮多少费用,太原肛周脓肿原因,太原哪里有大肠水疗,太原肛裂和内痣的区别,太原外痔手术痛吗,太原市痔疮怎么治疗,太原肛周脓肿需要多少钱

SAN FRANCISCO, June 23 (Xinhua) -- Facebook announced Thursday that Netflix CEO and Chairman Reed Hastings has joined the social network company's board of directors.Hastings, who successfully managed Netflix through an IPO in 2002, is expected to provide useful guidance for Facebook which plans to go public.As the most popular subscription-based movie and television show rental service in the United States, Netflix could also help Facebook figure out how to enter the business of music streaming and movies, which, CEO Mark Zuckerberg said at the eG8 Forum held in Paris last month, would be Facebook's next focus.The Facebook board seat could also help Netflix to catch up with the social evolution of the Internet with its 23.6 million subscribers in the U.S. and Canada."Reed is an entrepreneur and technologist who has led Netflix to transform the way people watch movies and TV," said Zuckerberg in a statement. "He has built a culture of continuous rapid innovation, something we share and work hard to build every day.""Facebook is propelling a fundamental change in how people connect with each other and share all kinds of content," said Hastings. "I'm looking forward to working with Mark and the rest of the board to help Facebook take advantage of all the opportunities ahead."

SAN FRANCISCO, June 28 (Xinhua) -- Google Android chief Andy Rubin said on Tuesday that the activations of Android-powered devices are growing at a rate of 4.4 percent on a weekly basis, with over 500,000 devices activated each day worldwide."There are now over 500,000 Android devices activated every day, and it's growing at 4.4 percent w/w," tweeted Rubin, Google's Senior Vice President of Mobile who oversees the development of Android, the open-source operating system for smartphones.Last month, Google said at its annual developer conference Google I/O that 400,000 Android devices were being activated each day, compared with 300,000 daily activations in December and 100, 000 in May 2010.More research data have shown Android system's soaring market share and popularity. Earlier this month, Internet market research company ComScore reported that Android remained the No. 1 smartphone operating system in the United States over the three months ending in April. The system captured 36.4 percent of U.S. smartphone subscribers, while Apple's iOS system for iPhone had 26 percent of all smartphone users.In April, market research company Gartner said in a forecast that the Android operating system will own 49.2 percent of the global smartphone market and Apple's iOS will have an 18.9-percent share in the second place.

RIO DE JANEIRO, July 28 (Xinhua) -- Brazilians are eating a lot of rice and beans as well as high-calorie junk food lacking nutrition, a study released Thursday by the Brazilian Institute of Geography and Statistics (IBGE) found.According to the study, over 90 percent of Brazilians eat daily helpings of fruits and vegetables lower than the levels recommended by the Health Ministry (400 grams). Also,the consumption of sugary drinks (juices, fruit drinks and soft drinks) is twice as high as recommended by the ministry.Rice and beans, along with coffee and juices, are the most popular in Brazilians' diet. Teenagers are the main consumers of those drinks, drinking twice as much as adults. Men eat less greens and fruits than women, but drink five times more alcohol.In urban areas, the consumption of beer, soft drinks, sandwiches, and salty bread is higher. Brazilians in rural areas have a healthier diet, richer in rice, beans, fish, cassava flour, and sweet potatoes.Along with a lack of physical activity, the Brazilians' poor diet was cited as one of the main causes of obesity in the country. According to a Health Ministry study published in April, 48 percent of Brazilians are overweight, and 15 percent are obese.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, June 28 (Xinhuanet) -- The figure of adults with diabetes has risen to 347 million worldwide, which is more than doubled in the past three decades, according to a study published in the British journal Lancet.The study, which analyzed data compiled from 2.7 million participants aged 25 and over from across the world, shows approximately 138 million in China have diabetes, and 36 million in the United States.Among high-income countries, diabetes rates were the highest in the U.S., Greenland, Malta, New Zealand, and Spain. The Netherlands, Austria, and France boasted the lowest rates, suggested the study published online by The Lancet journal on June 25.Majid Ezzati, a lead author of the study, said on Reuters: “Diabetes is becoming more common almost everywhere in the world.”Danaei added: “Unless we develop better programs for detecting people with elevated blood sugar and helping them to improve their diet and physical activity and control their weight, diabetes will inevitably continue to impose a major burden on health systems around the world.”